HER2-positive cancer companion diagnostic - Ventana

Drug Profile

HER2-positive cancer companion diagnostic - Ventana

Alternative Names: Pertuzumab companion diagnostic - Ventana; Trastuzumab companion diagnostic - Ventana; Trastuzumab emtansine companion diagnostic - Ventana; Ventana HER2 (4B5) IHC companion diagnostic assay; Ventana HER2/neu (4B5) Rabbit Monoclonal Primary Antibody Assay

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ventana Medical Systems
  • Class Antibody diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer
  • No development reported Gastric cancer

Most Recent Events

  • 13 Apr 2016 No recent reports on development identified - Registered for Breast cancer (Diagnosis) in USA (unspecified route)
  • 13 Apr 2016 No recent reports on development identified - Registered for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 13 Dec 2013 Clinical trials in Breast cancer (diagnosis) in European Union, Canada, Japan and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top